Fig. 1From: Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraineMonthly migraine respondera rates: (A) ≥50% and (B) ≥75%. aMigraine response was defined as a reduction in monthly migraine days. MRR, migraine responder rateBack to article page